BR112015022197A8 - uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia - Google Patents
uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia Download PDFInfo
- Publication number
- BR112015022197A8 BR112015022197A8 BR112015022197A BR112015022197A BR112015022197A8 BR 112015022197 A8 BR112015022197 A8 BR 112015022197A8 BR 112015022197 A BR112015022197 A BR 112015022197A BR 112015022197 A BR112015022197 A BR 112015022197A BR 112015022197 A8 BR112015022197 A8 BR 112015022197A8
- Authority
- BR
- Brazil
- Prior art keywords
- cataplexy
- medicament
- manufacture
- compound
- pharmaceutical composition
- Prior art date
Links
- 208000001573 Cataplexy Diseases 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/02—Carbamic acids; Salts of carbamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
Abstract
treatment of cataplexy abstract the present invention relates to a method of treating cataplexy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds. _____________________________________________________ resumo patente de invenção: "tratamento de cataplexia". a presente invenção se refere a um método para o tratamento de cataplexia em um indivíduo com necessidade do mesmo, compreendendo administrar ao indivíduo a uma quantidade terapeuticamente eficaz de determinados compostos carbamato.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361778998P | 2013-03-13 | 2013-03-13 | |
US61/778,998 | 2013-03-13 | ||
PCT/US2014/023969 WO2014164969A1 (en) | 2013-03-13 | 2014-03-12 | Treatment of cataplexy |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112015022197A2 BR112015022197A2 (pt) | 2017-07-18 |
BR112015022197A8 true BR112015022197A8 (pt) | 2019-11-26 |
BR112015022197B1 BR112015022197B1 (pt) | 2022-06-07 |
Family
ID=51530017
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015022197-1A BR112015022197B1 (pt) | 2013-03-13 | 2014-03-12 | Uso de um composto para o tratamento de cataplexia |
Country Status (22)
Country | Link |
---|---|
US (6) | US9359290B2 (pt) |
EP (1) | EP2968208B1 (pt) |
JP (2) | JP6530741B2 (pt) |
KR (1) | KR102192554B1 (pt) |
CN (1) | CN105431142B (pt) |
AU (1) | AU2014248849B2 (pt) |
BR (1) | BR112015022197B1 (pt) |
CA (1) | CA2905457A1 (pt) |
DK (1) | DK2968208T3 (pt) |
ES (1) | ES2927675T3 (pt) |
HK (1) | HK1219236A1 (pt) |
HR (1) | HRP20221018T1 (pt) |
HU (1) | HUE060060T2 (pt) |
MX (1) | MX2015012644A (pt) |
MY (1) | MY177740A (pt) |
PH (1) | PH12015502075A1 (pt) |
PT (1) | PT2968208T (pt) |
RU (2) | RU2689984C2 (pt) |
SG (1) | SG11201507121RA (pt) |
SI (1) | SI2968208T1 (pt) |
TW (2) | TWI684450B (pt) |
WO (1) | WO2014164969A1 (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1890684T3 (pl) * | 2005-06-08 | 2014-05-30 | Sk Biopharmaceuticals Co Ltd | Leczenie zaburzeń snu i czuwania |
EP2445490B1 (en) | 2009-06-22 | 2023-02-08 | SK Biopharmaceuticals Co., Ltd. | Methods for treating or preventing fatigue |
PT2968208T (pt) * | 2013-03-13 | 2022-10-28 | Aerial Biopharma Llc | Tratamento da cataplexia |
PL3021838T3 (pl) | 2013-07-18 | 2021-03-08 | Jazz Pharmaceuticals Ireland Limited | Leczenie otyłości |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US10195151B2 (en) | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
WO2018048871A1 (en) | 2016-09-06 | 2018-03-15 | Jazz Pharmaceuticals International Iii Limited | Solvate form of (r)-2-amino-3-phenylpropyl carbamate |
WO2018067971A1 (en) | 2016-10-06 | 2018-04-12 | Jazz Pharmaceuticals International Iii Limited | Carbamoyl phenylalaninol compounds and uses therof |
MX2019014409A (es) | 2017-06-02 | 2022-03-17 | Jazz Pharmaceuticals Ireland Ltd | Métodos y composiciones para tratar somnolencia excesiva. |
EP3661911A4 (en) | 2017-07-31 | 2021-04-14 | Jazz Pharmaceuticals Ireland Limited | CARBAMOYL-PHENYLALANINOL ANALOGS AND USES THEREOF |
US20190076409A1 (en) * | 2017-09-12 | 2019-03-14 | Ovid Therapeutics Inc. | Use of gaboxadol in the treatment of narcolepsy |
US20210106522A1 (en) | 2018-01-29 | 2021-04-15 | Cognos Therapeutics, Inc. | Intratumoral delivery of bortezomib |
US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
WO2021113163A1 (en) * | 2019-12-03 | 2021-06-10 | Axsome Therapeutics, Inc. | Use of reboxetine to treat nervous system disorders |
EP3866768A4 (en) * | 2018-10-15 | 2022-01-05 | Axsome Therapeutics, Inc. | USING REBOXETINE TO TREAT NARCOLEPSY |
US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
CA3127871A1 (en) | 2019-03-01 | 2020-09-10 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
KR20220108122A (ko) * | 2019-12-03 | 2022-08-02 | 액섬 테라퓨틱스, 인크. | 신경계 장애 치료를 위한 레복세틴의 용도 |
US10940133B1 (en) | 2020-03-19 | 2021-03-09 | Jazz Pharmaceuticals Ireland Limited | Methods of providing solriamfetol therapy to subjects with impaired renal function |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US178429A (en) * | 1876-06-06 | Improvement in hulling-machines | ||
JPS58156351A (ja) * | 1982-03-11 | 1983-09-17 | Sumitomo Chem Co Ltd | メタクリル酸合成触媒の再生方法 |
CZ285762B6 (cs) | 1993-06-10 | 1999-11-17 | Eli Lilly And Company | Farmaceutický prostředek vhodný pro prevenci dávení a zvracení a pro ošetřování sexuální dysfunkce savců a jeho použití |
KR100197892B1 (ko) | 1994-09-09 | 1999-06-15 | 남창우 | 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법 |
US5756817C1 (en) | 1995-02-11 | 2001-04-17 | Sk Corp | O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same |
KR0173862B1 (ko) | 1995-02-11 | 1999-04-01 | 조규향 | O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
KR0173863B1 (ko) | 1995-04-10 | 1999-04-01 | 조규향 | 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
ES2170878T3 (es) | 1996-10-10 | 2002-08-16 | Sk Corp | Compuestos de o-carbamoil-fenilalaninol y sus sales farmaceuticamente utiles. |
AU4674797A (en) | 1996-10-22 | 1998-05-15 | Ortho Pharmaceutical Corporation | Phenylalaninol derivatives for the treatment of central nervous system disorders |
US6204245B1 (en) * | 1999-09-17 | 2001-03-20 | The Regents Of The University Of California | Treatment of narcolepsy with immunosuppressants |
GB0109103D0 (en) * | 2001-04-11 | 2001-05-30 | Pfizer Ltd | Novel compounds |
US20030207857A1 (en) | 2001-04-11 | 2003-11-06 | Adam Mavis D. | Phenyl heterocyclyl ethers |
US20050080268A1 (en) | 2003-10-08 | 2005-04-14 | Yong-Moon Choi | Process of preparing O-carbamoyl compounds in the presence of active amine group |
ATE490959T1 (de) | 2004-03-31 | 2010-12-15 | Janssen Pharmaceutica Nv | Heterocyclische nichtimidazolverbindungen als modulatoren des histamin-h3-rezeptors |
KR20070100686A (ko) * | 2004-09-07 | 2007-10-11 | 오르펀 메디칼, 인크. | 개선된 ghb 조성물 |
JP2008518921A (ja) | 2004-10-28 | 2008-06-05 | エスケー ホルディングス カンパニー リミテッド | うつ病のための補助療法 |
PL1890684T3 (pl) | 2005-06-08 | 2014-05-30 | Sk Biopharmaceuticals Co Ltd | Leczenie zaburzeń snu i czuwania |
JP5298334B2 (ja) | 2005-06-22 | 2013-09-25 | エスケー ホルディングス カンパニー リミテッド | 性機能障害を治療する方法 |
EA019935B1 (ru) | 2005-07-26 | 2014-07-30 | Янссен Фармацевтика Н.В. | Способы лечения алкогольной абстиненции |
FR2903904A1 (fr) * | 2006-07-21 | 2008-01-25 | Bioprojet Soc Civ Ile | Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3 |
JP2010506845A (ja) | 2006-10-13 | 2010-03-04 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | フェニルアルキルアミノカルバメート組成物 |
WO2008055314A1 (en) * | 2006-11-10 | 2008-05-15 | Dimerix Bioscience Pty Ltd | Thyrotropin releasing hormone receptor-orexin receptor hetero-dimers/-oligomers |
EP2445490B1 (en) | 2009-06-22 | 2023-02-08 | SK Biopharmaceuticals Co., Ltd. | Methods for treating or preventing fatigue |
US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
AU2010316106B2 (en) | 2009-11-06 | 2015-10-22 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
MX350745B (es) | 2009-11-06 | 2017-09-14 | Sk Biopharmaceuticals Co Ltd * | El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia. |
US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
PT2968208T (pt) * | 2013-03-13 | 2022-10-28 | Aerial Biopharma Llc | Tratamento da cataplexia |
-
2014
- 2014-03-12 PT PT147780886T patent/PT2968208T/pt unknown
- 2014-03-12 KR KR1020157027978A patent/KR102192554B1/ko active IP Right Grant
- 2014-03-12 SI SI201431991T patent/SI2968208T1/sl unknown
- 2014-03-12 BR BR112015022197-1A patent/BR112015022197B1/pt active IP Right Grant
- 2014-03-12 RU RU2015143610A patent/RU2689984C2/ru active
- 2014-03-12 WO PCT/US2014/023969 patent/WO2014164969A1/en active Application Filing
- 2014-03-12 TW TW108107074A patent/TWI684450B/zh active
- 2014-03-12 HR HRP20221018TT patent/HRP20221018T1/hr unknown
- 2014-03-12 JP JP2016501395A patent/JP6530741B2/ja active Active
- 2014-03-12 US US14/205,423 patent/US9359290B2/en active Active
- 2014-03-12 TW TW103108612A patent/TWI663971B/zh active
- 2014-03-12 ES ES14778088T patent/ES2927675T3/es active Active
- 2014-03-12 HU HUE14778088A patent/HUE060060T2/hu unknown
- 2014-03-12 SG SG11201507121RA patent/SG11201507121RA/en unknown
- 2014-03-12 DK DK14778088.6T patent/DK2968208T3/da active
- 2014-03-12 AU AU2014248849A patent/AU2014248849B2/en active Active
- 2014-03-12 MX MX2015012644A patent/MX2015012644A/es unknown
- 2014-03-12 CN CN201480027152.9A patent/CN105431142B/zh active Active
- 2014-03-12 CA CA2905457A patent/CA2905457A1/en not_active Abandoned
- 2014-03-12 RU RU2019114940A patent/RU2019114940A/ru not_active Application Discontinuation
- 2014-03-12 MY MYPI2015703166A patent/MY177740A/en unknown
- 2014-03-12 EP EP14778088.6A patent/EP2968208B1/en active Active
-
2015
- 2015-09-11 PH PH12015502075A patent/PH12015502075A1/en unknown
-
2016
- 2016-05-09 US US15/149,478 patent/US9585863B2/en active Active
- 2016-06-23 HK HK16107350.1A patent/HK1219236A1/zh unknown
-
2017
- 2017-01-30 US US15/419,133 patent/US10259780B2/en active Active
-
2019
- 2019-03-20 US US16/359,446 patent/US11072579B2/en active Active
- 2019-05-17 JP JP2019093823A patent/JP2019147830A/ja active Pending
-
2021
- 2021-07-23 US US17/383,707 patent/US11713292B2/en active Active
-
2023
- 2023-06-19 US US18/337,299 patent/US20230416195A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
UA109991C2 (xx) | Карбаматні сполуки, їх отримання і застосування | |
BR112015003188A2 (pt) | Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
BR112015007778A2 (pt) | profármacos neutralizantes de vegf para o tratamento de condições oculares | |
MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
BR112014031394A2 (pt) | composições e métodos para absorção transmucosa | |
EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
EA202090098A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
BR112014015568A2 (pt) | compostos carbamato de fenila para uso em prevenção ou tratamento de epilepsia | |
BR112012033738A2 (pt) | método para o tratamento de transtorno bipolar | |
MX340985B (es) | Compuestos de n-heteroarilo. | |
TW201613578A (en) | Pharmaceutical combinations | |
BR112013021566A2 (pt) | composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula | |
EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
EA201590193A1 (ru) | Препараты лаквинимода без подщелачивающего агента | |
EA201791432A1 (ru) | Композиции на основе пролекарства монометилфумарата | |
BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
EA201591507A1 (ru) | Лечение рассеянного склероза лахинимодом | |
BR112016008060A8 (pt) | composto, formulação farmacêutica, processo para preparar um composto de fórmula (i), método para preparação de um composto, uso do composto ou sal farmaceuticamente aceitável do mesmo | |
BR102012028120B8 (pt) | Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento | |
EA201991531A1 (ru) | Способы лечения композициями линаклотида с отсроченным высвобождением | |
EA201591180A1 (ru) | Составы ингибитора lfa-1 | |
BR112018002763A2 (pt) | método para cicatrização de ferimentos | |
BR112015007095A8 (pt) | derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados, composição farmacêutica compreendendoos e uso dos referidos derivados |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: SK BIOPHARMACEUTICALS CO., LTD. (KR) ; JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/03/2014, OBSERVADAS AS CONDICOES LEGAIS |